Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of leadership in healthcare and technology, and extensive global board experience. She is the CEO of Gallop Oncology, a clinical stage biotech. She has founded and served as Managing Partner of Dana Farber Cancer Institute venture fund, and CEO and board chair of multiple life sciences companies including Kojin Tx. She is an Entrepreneur-in-Residence at PureTech, where she plays a key role in advancing oncology programs. Luba has a proven track record of building world-class teams and companies, leading over $15B in deals and investments across therapeutics, diagnostics, and life sciences globally. She has held leadership roles at Google (Verily) and Roche, where as VP of Global Business Development & M&A, she spearheaded diagnostics BD and established the East Coast Innovation Hub. Recognized as an industry thought leader, she advises CEOs of top academic institutions, including Dana-Farber Cancer Institute and Wyss Center. She serves on the Investor Committee for National Cancer Institute and contributes to NEJM Catalyst. Luba is a strategic leader in digital transformation, AI, M&A, financing, and governance, with expertise in scaling companies, guiding high-impact transactions, and driving innovation at the intersection of biotech and technology. A former lawyer at WilmerHale, Luba is an expert in regulatory, IP, and corporate law. She has served as a Harvard University lecturer and sits on multiple public and private boards, including In8Bio, BenchSci, Stalicla, Abcam (where she led its sale to Danaher), Closed Loop Medicine, and MassBio.

Skip Kelly is a managing director and relationship executive in the Venture Capital (VC) coverage group for J.P. Morgan Commercial Banking. Comprised of venture experts with deep connectivity to the Innovation Economy, Skip joins the group committed to creating a supportive ecosystem for VC firms and their portfolio companies. To address the unique and holistic needs of VCs, he partners closely with Life Science and Healthcare relationship bankers to deliver global solutions to their portfolio companies across every stage of growth. In his role, Skip is also responsible for developing relationships at the national level with key VC firms from his location in Boston. Skip joined J.P. Morgan in January 2021, after 17 years with Silicon Valley Bank. He has worked in a number of roles including technology, advisory services/special assets and life sciences and healthcare. Most recently, he was Head of US Credit Solutions where he and team developed a host of creative debt financing solutions for all sectors across Life Science and Healthcare – Biotechnology, Diagnostics, Tools, Medical Device and Healthcare IT. Skip earned a bachelor’s degree in finance from Boston College. After growing up in the hospitality business in Southern Maine, good food and good company is still a passion. Skip, his wife and their three kids make their home in Andover, MA.

David Lucchino has been a leader in the life science industry for more than two decades, as an executive, an entrepreneur, an investor and an advocate. He was recently named President and CEO of Brenig Therapeutics, a biotech company developing small molecule therapeutics for neurodegenerative diseases. Prior to Brenig, he was the President and CEO of Frequency Therapeutics, a company he co-founded in 2014 and took public in 2019. Frequency was as a regenerative medicine company, born out of the labs of the renown MIT Institute Professor Robert Langer, with programs for sensorineural hearing loss and remyelination in multiple sclerosis. In 2005, David co-founded Semprus BioSciences (also with Dr. Langer). There he guided its lead product, a device that reduces blood clotting on medical devices, to FDA approval and European CE-Marking. Semprus was subsequently sold to Teleflex (NYSE: TFX). Previously, David worked at the Boston-based venture capital firm Polaris Partners, where he focused on healthcare investing and portfolio company board recruitment. He began his career as a co-founder and managing director at LaunchCyte, a venture incubator based out of the University of Pittsburgh Medical Center that helped form several biotech startups. David is the past Chairman of MassBio and remains a board member. He was appointed by former Governor Charlie Baker to the Massachusetts STEM Advisory Council and is a member of the College of Fellows for the American Institute of Medical and Biological Engineering. David also serves on the boards of the Multiple Myeloma Research Foundation and Siloam Vision David earned a B.A. from Denison University, an M.S. from the Newhouse School of Public Communications at Syracuse University, and an M.B.A. from the MIT Sloan School of Management as an Alfred P. Sloan Fellow.